Skye生物科学执行官出售股票,但分析师仍建议购买公司股份。 Skye Bioscience executives sold stock, but analysts still recommend buying the company's shares.
斯凯生物科学公司的CEO Punit Dhilon和其他高管出售了相当一部分公司股票,减少了所有权。 CEO Punit Dhillon and other executives at Skye Bioscience sold significant portions of their company stock, reducing their ownership. Skye生物科学开发出治疗传染病的基于大麻素的分子。 Skye Bioscience develops cannabinoid-based molecules for treating infectious diseases. 尽管最近进行了股票销售,分析师仍保持“Buy”评级,平均目标价格为18.67美元,高于现值。 Despite recent stock sales, analysts maintain a "Buy" rating with an average target price of $18.67, up from the current value. 机构投资者也增加了在公司中的股份。 Institutional investors also increased their stakes in the company.